The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.
An article from
Dive Brief
The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.
Published Sept. 3, 2026
Permission granted by Ultragenyx
'Fall From Grace' — Biotech Crashes 44% To A Record Low
Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patients
Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?
The company's experimental Angelman syndrome treatment failed.
Ultragenyx's Phase 3 Aspire trial of apazunersen misses its primary and key secondary endpoints in Angelman syndrome, sending…
The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s…
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a…
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel…
Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman…
